Overview

Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia

Status:
Unknown status
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life. Based on a previous study in patients with AIDS, possible benefits may include improved appetite and strength; weight gain, improved mood; and decreased fatigue.
Phase:
Phase 2
Details
Lead Sponsor:
Ohr Pharmaceutical Inc.